Substance acting to prevent and improve cerebral function disorder and process for preparing the same

A process for manufacturing a preparation for normalizing electroencephalogram abnormalities and consciousness disturbance induced by anoxia, having the following properties:

• Appearance and Properties:
• colorless and odorless
• Solubility:
• easily soluble in water, hardly soluble in alcohol, acetone and ether
• Stability:
• stable at room temperature, stable under freezing and defrosting
• Ultraviolet Absorption Spectrum:
• maximum absorption at 280 nm
• Molecular Weight:
• 1000 .about. 3000
• Color reaction:
• positive in ninhydrin
• Thin layer Chromatography:
• Rf = 0.355 .+-. 0.075
• plate:
• microcrystalline cellulose
• Developing Solvent:
• n-butanol:acetic acid:water = 3:1:1
• Conditions for Developing:
• room temperature
• Color Reaction:
• ninhydrin,
• comprising the steps of:
• 1. adding a fatty acid of 16-20 carbon atoms to an aqueous albumin solution in an amount sufficient to cause conjugation, said albumin being selected from the group consisting of egg albumin and bovine serum albumin, thereby reacting the albumin with the fatty acid to form modified albumin;
• 2. collecting the modified albumin, dissolving the modified albumin in a small amount of water to form an aqueous modified albumin solution, and adding pronase thereto, thereby hydrolyzing the modified albumin;
• and
• 3. carrying out a column chromatography using dextran gel or sulfonic acid type ion exchange resin having a molecular weight fractionation range of 1,000 - 5,000 and collecting the fraction acting to inhibit deactivation of DNP-ATPase.